Goldman Sachs expects Nvidia ’beat and raise,’ lifts price target to $240
Decheng Capital China Life Sciences USD Fund III, L.P., a ten percent owner of BeyondSpring Inc. (NASDAQ: BYSI), sold 20,046 shares of the company’s stock between September 9 and September 11, 2025. The sales, conducted in multiple transactions, fetched prices ranging from $1.90 to $1.97, totaling approximately $40,866. According to InvestingPro analysis, the $76.6M market cap company appears overvalued at current levels, with concerning financial metrics including rapid cash burn and negative profitability.
The sales were executed in three separate transactions. On September 9, 9,050 shares were sold at a weighted average price of $1.97. The following day, September 10, 8,176 shares were sold at an average price of $1.93. The final transaction occurred on September 11, with 3,820 shares sold at an average price of $1.90. InvestingPro subscribers can access 7 additional key insights about BeyondSpring’s financial health and future prospects.
Following these transactions, Decheng Capital China Life Sciences USD Fund III, L.P. directly holds 1,874,710 shares.
Decheng Capital China Life Sciences USD Fund II, L.P. holds 1,617,409 shares, and Decheng Capital Global Healthcare Fund (Master), LP holds 891,734 shares in BeyondSpring Inc .
In other recent news, BeyondSpring Inc. announced positive results from a clinical study involving its lead drug, Plinabulin. The study, published in Med (Cell Press), demonstrated that the combination of Plinabulin with radiation and checkpoint inhibitors showed efficacy in patients who had previously not responded to immune checkpoint inhibitor therapy. Specifically, the Phase 1 translational trial revealed a 23% objective response rate and a 54% disease control rate in non-irradiated lesions among evaluable patients. Additionally, BeyondSpring has scheduled its 2025 annual meeting of shareholders for September 15, 2025. The record date for the meeting has been set for the close of business on July 25, 2025. Shareholder proposals for the meeting must comply with Rule 14a-8 of the Securities Exchange Act and be submitted by July 14, 2025. These recent developments reflect BeyondSpring’s ongoing efforts in clinical research and shareholder engagement.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.